The indexes are near all-time highs in what is now the oldest bull market and recovery in history. And risks are mounting. There’s the trade war with China, the sputtering global economy, weaker growth at home and impeachment. The market is really struggling muster...
Read More
October is a historically ominous month for stocks. After all, it is the month of the 1929 stock market crash and the 1987 crash. After a rough May and August we step into the mother of all jinxed months with a terrible start.
Read More
Profit from the American Energy Export Boom
One of the constants in life is change. The winds of change seem to swoop in and disrupt things we mistakenly consider permanent. Understanding exactly when and where such events occur is crucial to successful investing.
One such change...
Read More
It’s one of those special days in the market where the Fed will make a highly anticipated decision on interest rates. It is widely expected that the Central Bank will cut the Fed Funds rate by 0.25%.
Read More
The overall market appears to be largely pricing in a continued trade war with China and a slowing global economy. It’s also pricing in a rate cut this month and more to follow. The indexes appear to want to forge higher provided trade don’t...
Read More
The economy is still solid and the market isn’t overpriced in this low interest rate world. The S&P 500 is only 2% higher than it was in January of 2018, 20 months ago. The stock market is still the best place to be. spikes...
Read More
Defense is the Best Offer
Here we are in the tenth year of an economic recovery and bull market. All recoveries end in recession and all bull markets end in bear markets. Both have already well exceeded the average historical life spans. In fact, is...
Read More
The Dog Days of Summer
We are in the dog days of summer, the hottest, most sultry days of the year. The expression “dog days” is an old one. In fact, it’s really old. The Romans used it.
It’s one of those expressions that everyone but...
Read More
TABLE OF CONTENTS
This Month's Featured Buy: Valero Energy (VLO) | Portfolio At A Glance | Portfolio Updates | Changes Since Last Week’s Update: AbbVie (ABBV) Buy to Hold, McCormick & Co. (MKC) Hold to Sell Half | Dividend Calendar | The Rate Cut Cautious...
Read More
The Incredible Opportunity of 5G
Technology seems to provide us with new English words all the time. Nobody ever heard the terms “tweet” or “selfie” or “photobomb” just a few years ago. So many new terms are thrown around that it’s tempting to ignore of...
Read More
Exploit the Accelerating Technological Revolution
We have a tendency to focus on our everyday lives without truly appreciating how the world is changing around us. But understanding the tectonic shifts outside of our near-term consciousness is crucial to successful investing.
I realized the other day I’ve...
Read More
Profit from the Great Global Infrastructure Crisis
Have you ever lost power in your house? I lost power for a week a few years ago after Hurricane Sandy. It was unbearable. My wife and son fled to my mother-in-law’s house and I stayed home mind...
Read More
Cash in on the American Energy Revolution
Do you ever get the feeling that the media focuses only on the bad news? Frankly, since discovering binge watching on Netflix and Amazon, I don’t even watch the news anymore. You have to look beyond the politics,...
Read More
Profit from Our Great Societal Transformation
Markets go up and down. It happens. There will be bull markets and bear markets. Different administrations will come into power. Change is one of the few constants in life and investing.
But certain powerful and ascendant trends will regardless...
Read More
Should I Stay or Should I Go?
by Tom Hutchinson
My name is Tom Hutchinson. Starting next month I will be taking over as Chief Analyst of Cabot Dividend Investor. I’m excited to share the fruits of my life’s work and passion by giving you and...
Read More
Approaching Neutral
The major stock market indexes tacked on more losses last week, even though markets were only open for three-and-a-half days and trading was relatively light. The Nasdaq closed the week 4.3% lower, the Dow was down 4.4%, and the S&P 500 lost But...
Read More
Buying biotech stocks seems like a contrarian play at the moment. But it made one day trader a lot of money. Here's what it says about the current market.
Read More
This global pharma stock declined after merger buzz collapsed, but is gaining notice since the FDA just approved its new lung cancer drug. The shares have a current dividend yield of 2.88%, paid twice a year.
AstraZeneca (AZN)
From 2 for 1 Stock Split Newsletter
AstraZeneca was...
Read More
By Paul Goodwin
Editor, Cabot China & Emerging Markets Report
Here are the 24 Top Stocks of 2011. I screened the entire market to eliminate penny stocks and thinly traded issues that didn’t average 50,000 shares traded per day.
The overarching lesson of this list that...
Read More
Six out of the ten best-performing stocks of 2011 were in the medicine business.
Read More
